| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J2357 |
Injection, omalizumab, 5 mg |
6,581 |
4,383 |
$6.50M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
49,974 |
46,404 |
$2.32M |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
10,849 |
10,767 |
$2.06M |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
11,861 |
11,668 |
$1.49M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
9,984 |
9,924 |
$938K |
| 94060 |
|
25,518 |
25,059 |
$702K |
| 95117 |
|
108,726 |
36,048 |
$698K |
| 95024 |
|
7,376 |
7,335 |
$553K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,237 |
2,173 |
$155K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
11,074 |
8,689 |
$144K |
| 95115 |
|
19,435 |
6,711 |
$103K |
| 96401 |
|
1,246 |
995 |
$98K |
| J0517 |
Injection, benralizumab, 1 mg |
26 |
25 |
$56K |
| 95044 |
|
277 |
273 |
$55K |
| 90674 |
|
679 |
672 |
$18K |
| 94726 |
|
480 |
478 |
$16K |
| 94729 |
|
450 |
449 |
$16K |
| G0008 |
Administration of influenza virus vaccine |
1,072 |
1,065 |
$10K |
| 94010 |
|
264 |
264 |
$5K |
| 90688 |
|
230 |
230 |
$4K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
52 |
52 |
$3K |
| 94664 |
|
1,168 |
1,135 |
$3K |
| 90661 |
|
85 |
85 |
$3K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
467 |
397 |
$2K |
| 90756 |
|
68 |
68 |
$2K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
118 |
113 |
$1K |
| 95076 |
|
13 |
12 |
$883.12 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
34 |
34 |
$652.59 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
31 |
30 |
$246.42 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
586 |
558 |
$1.11 |
| G9907 |
Documentation of medical reason(s) for not providing tobacco cessation intervention on the date of the encounter or within the previous 12 months (e.g., limited life expectancy, other medical reason) |
41 |
39 |
$0.20 |
| G8484 |
Influenza immunization was not administered, reason not given |
140 |
135 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
1,055 |
993 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
745 |
704 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
812 |
763 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
236 |
228 |
$0.00 |
| 4040F |
|
176 |
170 |
$0.00 |
| 4004F |
|
53 |
49 |
$0.00 |
| 1123F |
|
70 |
67 |
$0.00 |
| C9399 |
Unclassified drugs or biologicals |
40 |
30 |
$0.00 |
| 1036F |
|
802 |
761 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
83 |
81 |
$0.00 |